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Abstract 
Background: We present the case of a 64-year-old patient who presented to his primary 
care physician with fatigue, worsening shortness of breath, abdominal discomfort and a 
rapidly growing abdominal girth, although he had lost 5 kg of weight within 3 months. 
He had a history of untreated hypertension, compensated renal insufficiency and COPD. 
Despite weight loss and fatigue, the patient did not experience any other constitutional 
symptoms such as fever, night sweats or loss of appetite.  
Investigations: Physical examination, blood tests, CT scan of the abdomen, MRI scan of 
the abdomen, fine needle biopsy, excisional biopsy, Video Capsule Endoscopy, histology, 
PET scan.  
Diagnosis: Inflammatory myofibroblastic tumor, chylous ascites, chyloperitoneum.  
Management: Systemic chemotherapy, total parenteral nutrition and octreotide 
therapy.  
Conclusion: We describe the case of a patient in whom two extremely rare phenomena 
are present in combination: the diagnosis of an inflammatory myofibroblastic tumor and 
chylous ascites. While the tumor could be stabilized by different regimens of 
chemotherapy, the chyloperitoneum was treated with parenteral nutrition and 
subcutaneous octreotide injections, which resulted in a significant reduction of the 
amount of chylous ascites drained during regular paracentesis. 
 
Case Report 
We report a 64-year-old patient who presented to his primary care physician with fatigue, worsening 
shortness of breath, abdominal discomfort and a rapidly growing abdominal girth. The patient had lost 
5 kg of weight within the last 3 months. He had been well until 3 months prior to his first visit at his  
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primary care physician. Furthermore, the patient had a history of COPD, hypertension and 
compensated renal insufficiency. 
A CT as well as a subsequent MRI scan (fig. 1) revealed a large tumor of the upper left abdomen 
infiltrating the entire mesentery and the omentum majus. The tumor was up to 15 cm in diameter and 
ascites could be found radiologically. A fine needle biopsy of the abdominal mass was performed at 
another hospital, but not enough tissue could be obtained for a diagnosis to be made. Subsequently, the 
patient underwent a laparoscopy for biopsy, which confirmed the diagnosis of an inflammatory 
myofibroblastic tumor. During the procedure, a cloudy and milky fluid could be drained, which was 
likely to be chylous ascites. The milky fluid could be collected in wound drainage for several days after 
surgery. 
The patient was transferred to our medical oncology clinic. On admission, the patient presented with 
large and distended abdomen. Abdominal ultrasound examination confirmed ascites, and abdominal 
paracentesis drained 4 liters of milky fluid (fig. 2). Biochemical analysis confirmed the diagnosis of 
chylous ascites. Total protein content was 46.3 g/l; glucose was 103 mg/dl. Cholesterol and triglyceride 
concentrations were 301 and 702 mg/dl, respectively. Serum triglyceride levels were not elevated (159 
mg/dl). Cytological examination found 910 cells showing a few activated mesothelial cells, but no tumor 
cells or signs of infection could be seen. 
We presented the case to our Department of Surgery at the University of Heidelberg. Due to the size 
and the massive tumor infiltration of the mesentery, radical resection was judged to be impossible. 
Therefore, we decided to treat the patient with a chemotherapy regimen consisting of etoposide 125 
mg/m
2/day administered on day 1 and 4, ifosfamide 1,500 mg/m
2/day on day 1–4 and adriamycin 50 
mg/m
2/day on day 1 (EIA regimen, repetition day 22). A MRI scan after 2 cycles of chemotherapy did 
not show any shrinkage of the tumor and was therefore evaluated as stable disease. In addition, we 
performed a fluorodeoxyglycose positron emission tomography (PET) scan after these 2 cycles of 
chemotherapy, which did not reveal a significantly elevated fluorodeoxyglycose uptake of the abdominal 
tumor (maximal standard uptake value 4.4). This result underlines the tendency of the tumor to grow 
very slowly. Therefore, we decided together with the patient to discontinue aggressive chemotherapy. 
For the treatment of the chylous ascites, the patient was put on a low total parenteral nutrition 
(TPN). Subcutaneous octreotide therapy (Sandostatin; Novartis Pharmaceuticals, Nurnberg, Germany) 
was started (3 × 50 μg per day) after completion of the first cycle. As no significant side effects were 
noted, the octreotide dose was increased after one week of treatment to 3 × 100 μg per day, and after 
another week to 3 × 150 μg per day. Total parenteral nutrition was performed simultaneously to 
octreotide therapy. As a result of this therapeutic approach the amount of chylous ascites, which could 
be drained during regular paracentesis, was significantly reduced (fig. 3). Altogether, total parenteral 
nutrition and octreotide therapy were discontinued after 6 weeks. 
Follow-up assessment 2 months after completion of the first 2 cycles of chemotherapy showed a 
recurrence of the chyloperitoneum (fig. 3) as well as a mild tumor growth. At this point, we decided to 
continue with the parental nutrition as an overnight infusion because of the increased risk of permanent 
malnutrition, which had led to further weight loss of the patient. Because of life quality reasons the 
patient decided to eat as usual during daytime. Furthermore, we started to treat the patient with another 
chemotherapy regimen consisting of methotrexate (30 mg/m
2 day 1, 15, and 22), vinblastin (3 mg/m
2 
day 1, 15, and 22), doxorubicin (30 mg/m
2 day 2) and cyclophosphamid (200 mg/m
2 day 2), which was 
repeated once after 28 days. According to Dishop et al., this regimen was effective in inflammatory 
myofibroblastic tumors [1]. This approach helped to further reduce chylous ascites (fig. 3), but did not 
result in any tumor shrinkage, which could be proven by a follow-up MRI scan of the abdomen. In 
search of alternative therapeutic strategies we preformed a DOTA-D-Phe1-Tyr3-octreotide 
(DOTATOC) positron emission tomography CT, which unfortunately showed no somatostatin 
receptor expression of the abdominal tumor. Therefore, yttrium-90 labeled DOTATOC therapy was not 
indicated. The patient was then discharged home, continuing overnight parental nutrition. For 3 
months, the patient has been stable at home and paracentesis was necessary only once. 
Discussion of Diagnosis 
Inflammatory myofibroblastic tumors (IMT) are extremely rare lesions grouped within 
the family of fibroinflammatory disorders. Originally, they have been classified as benign. 
However, some have been shown to demonstrate chromosomal aberrations resulting in  
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locally aggressive behavior and rarely metastasis. Therefore, these destructive variants can 
be counted to the heterogeneous group of soft tissue sarcomas. They may arise in almost 
any organ system and have already been described in the lung, spleen, bladder, pancreas, 
liver, colon, peripheral nerves, and soft tissue. IMT have been predominantly found in 
children and young adults; nevertheless, they can affect all age groups [2]. The 
characteristic histopathological feature of these lesions is the myofibroblast showing a 
dominant spindle cell proliferation with a variable inflammatory component [3]. 
Clinically, these tumor lesions lead to mass effects and patients’ discomfort is usually the 
reason for medical consultation, which was the case in our patient, too [2]. The primary 
and curative therapeutic approach is surgery if the anatomic location is amenable to 
radical resection. If an extirpation is not possible, like in the case we have presented here, 
lesions are observed or treated with various regimens, including non-steroidal anti-
inflammatory agents, steroids, radiation, and chemotherapeutic drugs [1]. We decided to 
treat our patient with a chemotherapy regimen consisting of etoposide 125 mg/m
2/day 
administered on day 1 and 4, ifosfamide 1,500 mg/m
2/day on day 1–4 and adriamycin 50 
mg/m
2/day on day 1 (EIA regimen, repetition day 22). This regimen is well established for 
the neoadjuvant/adjuvant treatment of soft tissue sarcoma at our institution. MRI after 
two cycles of chemotherapy showed stable disease according to RECIST criteria. The EIA 
regimen was not effective to cause any shrinkage of the abdominal tumor. That is why we 
decided together with the patient to use a different regimen consisting of methotrexate 
(30 mg/m
2 day 1, 15, and 22), vinblastin (3 mg/m
2 day 1, 15, and 22), doxorubicin (30 
mg/m
2 day 2) and cyclophosphamid (200 mg/m
2 day 2), which was described to be 
effective in inflammatory myofibroblastic tumors by Dishop et al. [1]. After 2 cycles, a 
further MRI scan was performed showing no significant response of the inflammatory 
myofibroblastic tumor. At this point we decided not to continue chemotherapy because 
the role of chemotherapy in the treatment of inflammatory myofibroblastic tumors 
remains questionable. The majority of case reports that have demonstrated a benefit from 
chemotherapy in the treatment of inflammatory myofibroblastic tumors exists in the 
pediatric population. There is almost no experience in the treatment with chemotherapy 
of elderly patients suffering from inflammatory myofibroblastic tumors. In Kovach’s 
review, only 3 patients were treated with systemic chemotherapy, comprising schedules of 
vincristine, methotrexate, ifosfamide, carboplatin, etoposide and taxol with inconsistent 
benefits [2]. However, the length and composition of chemotherapy should be based on 
the aggressiveness and evidence of local invasion of the tumor. This information can be 
obtained partly by PET. As described we have performed a fluorodeoxyglycose PET scan 
after the first tow cycles of EIA, which showed no significantly elevated uptake of 
fluorodeoxyglycose (maximal standard uptake value 4.4). This data underlines the 
tendency of the tumor to grow very slowly and, therefore, its being insensitive to 
chemotherapy. 
Interestingly, another extremely rare phenomenon could be found in our patient. 
Abdominal paracentesis revealed cloudy fluid confirmed as chylous ascites which 
developed due to the massive tumor infiltration of the mesentery and the omentum 
majus. Chylous ascites is an uncommon finding with an incidence of approximately 1 per 
20,000 admissions [4]. Chylous ascites develops when the lymphatic flow between the 
bowel and the cisterna chyli is disrupted. Commonly, it is observed as a challenging 
complication of thoracic or abdominal surgery [5–7]. Furthermore, liver cirrhoses, 
infections or malignancies in particular lymphomas have been reported to cause chylous 
ascites as well [6, 8, 9]. Although there is no recent study, it is generally believed that the 
incidence has increased due to the longer survival of patients with cancer and more 
aggressive abdominal and cardiothoracic interventions.  
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There is no standard treatment of chylous ascites. Repeated paracentesis has been used 
but can induce severe malnutrition and even death. If treatment of the underlying cause 
of chylous ascites is impossible or success of the treatment is delayed, conservative 
treatment options involve a medium chain triglyceride-based diet or total parenteral 
nutrition [10]. However, existing experience is rare and most cases were reported in 
children. Total parenteral nutrition reduces the accumulation of chylous fluid in the 
peritoneal cavity, but a satisfactory outcome requires at least 3–4 weeks of treatment [11]. 
There is anecdotal experience in using the somatostatin analogue octreotide to decrease 
the intestinal blood flow and inhibit lymph secretion through somatostatin receptors in 
the intestinal wall, thereby improving chylous ascites. Two cases on successful treatment 
of chylous ascites with octreotide have been reported in children [11, 12]. Another case 
report describes the successful use of octreotide in a patient with chylous ascites after liver 
transplantation [13]. Octreotide represents a promising adjunct in the conservative 
treatment of chylous ascites. Recent development of a long-acting somatostatin analogue 
could even facilitate patient’s treatment options. 
We have put our patient on parenteral nutrition over night to avoid malnutrition. 
During the day, the patient decided to eat whatever he liked for life quality reasons. In 
addition, we initially treated the patient with subcutaneous octreotide injections for more 
than 1 month. This management led to a significant long term reduction of the chylous 
ascites and, therefore, can be recommended for even those patients where the underlying 
cause for chylous ascites can not be treated. 
 
 
 
 
 
Fig. 1. Initial MRI before start of therapy demonstrating a large tumor of the upper left abdomen 
infiltrating the mesenterium and the omentum majus. 
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Fig. 2. Chylous ascites. 
 
 
 
Fig. 3. Reduction of chylous ascites which could be drained during regular paracentesis. a Start of total 
parenteral nutrition and octreotide therapy. b Discontinuation of total parenteral nutrition and 
octreotide therapy. c Continuation of total parenteral nutrition. 
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